Inhibition of EGFR signaling by TKIs can selectively promote histologic transformation in tumor cells with specific genomic backgrounds (e.g., TP53 mutations and RB1 deletions), i.e., from epithelial lineage adenocarcinoma to neuroendocrine lineage SCLC. Here, EGFR is linked to neoplasm.